%0 Journal Article %T Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer %J Asian Pacific Journal of Cancer Prevention %I West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. %Z 1513-7368 %D 2015 %\ 12/01/2015 %V 16 %N 13 %P 5521-5524 %! Systematic Analysis of Icotinib Treatment for Patients with Non-Small Cell Lung Cancer %K Icotinib %K NSCLC %K Chemotherapy %K response rate %K Toxicity %R %X Purpose: This analysis was conducted to evaluate the efficacy and safety of icotinib based regimens in treatingpatients with non-small cell lung cancer (NSCLC). Methods: Clinical studies evaluating the efficacy and safetyof icotinib-based regimens with regard to response and safety for patients with NSCLC were identified usinga predefined search strategy. Pooled response rates of treatment were calculated. Results: With icotinib-basedregimens, 7 clinical studies which including 5,985 Chinese patients with NSCLC were considered eligible forinclusion. The pooled analysis suggested that, in all patients, the positive reponse rate was 30.1% (1,803/5,985)with icotinib-based regimens. Mild skin itching, rashes and diarrhea were the main side effects. No grade III orIV renal or liver toxicity was observed. No treatment-related death occurred in patients treated with icotinibbasedregimens. Conclusions: This evidence based analysis suggests that icotinib based regimens are associatedwith mild response rate and acceptable toxicity for treating Chinese patients with NSCLC. %U https://journal.waocp.org/article_31286_d2144cb630b2a108ee3f94c9ba6e06e5.pdf